Press Releases

Press Releases

Stay updated on the latest VistaGen News and get the details about important events, public financial reports, and our product pipeline updates.

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that the European Patent
Company on Track to Report Top Line Results Before Year End SOUTH SAN FRANCISCO, Calif., Oct. 8, 2019 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with
Company on Track to Report Topline Data Before Year End SOUTH SAN FRANCISCO, CA / ACCESSWIRE / August 15, 2019  /  VistaGen Therapeutics  (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2019 / VistaGen Therapeutics (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced financial results for its fiscal
Previously completed Phase 2a clinical study of PH10 demonstrated significant antidepressant effects without psychological side effects or safety concerns after only one week of administration Phase 2b clinical trial for treatment of Major Depressive Disorder (MDD) planned for second half 2020
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / June 25, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today reported financial results for its fiscal
Significant reduction of levodopa-induced dyskinesia by AV-101 observed in "gold standard" MPTP non-human primate model of Parkinson's disease, while maintaining antiparkinsonian activity of levodopa and without causing amantadine-like adverse effects SOUTH SAN FRANCISCO, CA / ACCESSWIRE / June 20,
New preclinical data involving pregabalin are consistent with peer-reviewed data involving gabapentin previously published in The Journal of Pain SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 30, 2019 /   VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2019 /  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need,
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 2, 2019  /  VistaGen Therapeutics  (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet need,